RU2001116566A - APPLICATION OF DIALKYLFUMARATES FOR THE TREATMENT OF REASONS "OWNERS AGAINST THE TRANSPLANT" AND AUTOIMMUNE DISEASES - Google Patents

APPLICATION OF DIALKYLFUMARATES FOR THE TREATMENT OF REASONS "OWNERS AGAINST THE TRANSPLANT" AND AUTOIMMUNE DISEASES

Info

Publication number
RU2001116566A
RU2001116566A RU2001116566/14A RU2001116566A RU2001116566A RU 2001116566 A RU2001116566 A RU 2001116566A RU 2001116566/14 A RU2001116566/14 A RU 2001116566/14A RU 2001116566 A RU2001116566 A RU 2001116566A RU 2001116566 A RU2001116566 A RU 2001116566A
Authority
RU
Russia
Prior art keywords
disease
graves
use according
group
autoimmune diseases
Prior art date
Application number
RU2001116566/14A
Other languages
Russian (ru)
Other versions
RU2215524C2 (en
Inventor
Раджендра К. ДЖОШИ
Ханс-Петер ШТРЕБЕЛЬ
Original Assignee
Фумафарм Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19853487A external-priority patent/DE19853487A1/en
Application filed by Фумафарм Аг filed Critical Фумафарм Аг
Publication of RU2001116566A publication Critical patent/RU2001116566A/en
Application granted granted Critical
Publication of RU2215524C2 publication Critical patent/RU2215524C2/en

Links

Claims (22)

1. Применение одного или более диалкилфумаратов для получения фармацевтической композиции для лечения реакций "хозяин против трансплантата" и реакций "трансплантат против хозяина" при трансплантациях органов и клеток, и для лечения аутоиммунных заболеваний, выбранных из группы, состоящей из юношеского диабета, тиреодита Хашимото, диффузного токсического зоба (болезни Грейвса или базедовой болезни), системной красной волчанки (SLE), ксеродерматоза (синдрома Шегрена), пернициозной анемии и хронического активного (люпоидного) гепатита.1. The use of one or more dialkyl fumarates for the preparation of a pharmaceutical composition for treating host versus transplant and transplant versus host reactions in organ and cell transplants, and for treating autoimmune diseases selected from the group consisting of juvenile diabetes, Hashimoto thyroiditis, diffuse toxic goiter (Graves' disease or Grave's disease), systemic lupus erythematosus (SLE), xerodermatosis (Sjogren's syndrome), pernicious anemia and chronic active (lupoid) hepatitis. 2. Применение по п. 1 одного или более диалкилфумаратов формулы
Figure 00000001

в которой R1 и R2 могут быть одинаковыми или разными, независимо друг от друга линейными, разветвленными или циклическими, насыщенными или ненасыщенными C1-20-алкильными остатками, которые в случае необходимости могут быть замещены галогеном (хлор, фтор, йод, бром), гидроксигруппой, C1-4-алкоксигруппой, нитрогруппой или цианогруппой, пригодных для получения фармацевтической композиции для применения в трансплантационной медицине или для терапии аутоиммунных заболеваний, выбранных из группы, состоящей из юношеского диабета, тиреоидита Хашимото, диффузного токсического зоба (болезни Грейвса или базедовой болезни), системной красной волчанки (SLE), ксеродерматоза (синдрома Шегрена), пернициозной анемии и хронического активного (люпоидного) гепатита.2. The use according to claim 1 of one or more dialkyl fumarates of the formula
Figure 00000001

in which R 1 and R 2 can be the same or different, independently from each other linear, branched or cyclic, saturated or unsaturated C 1-20 -alkyl residues, which, if necessary, can be replaced by halogen (chlorine, fluorine, iodine, bromine ), a hydroxy group, a C 1-4 alkoxy group, a nitro group or a cyano group, suitable for preparing a pharmaceutical composition for use in transplant medicine or for treating autoimmune diseases selected from the group consisting of juvenile diabetes, Hashi thyroiditis moto, diffuse toxic goiter (Graves 'disease or Graves' disease), systemic lupus erythematosus (SLE), xerodermatosis (Sjogren's syndrome), pernicious anemia and chronic active (lupoid) hepatitis. 3. Применение по п. 2, в котором остатки R1 и R2 обозначают метил, этил, н-пропил, изопропил, н-бутил, втор. -бутил, трет. -бутил, пентил, циклопентил, 2-этилгексил, гексил, циклогексил, гептил, циклогептил, октил, винил, аллил, 2-гидроксиэтил, 2- и/или 3-гидроксипропил, 2-метоксиэтил, метоксиэтил или 2- или 3-метоксипропил.3. The use of claim 2, wherein R 1 and R 2 are methyl, ethyl, n-propyl, isopropyl, n-butyl, sec. -butyl, tert. -butyl, pentyl, cyclopentyl, 2-ethylhexyl, hexyl, cyclohexyl, heptyl, cycloheptyl, octyl, vinyl, allyl, 2-hydroxyethyl, 2- and / or 3-hydroxypropyl, 2-methoxyethyl, methoxyethyl or 2- or 3-methoxypropyl . 4. Применение по п. 3, в котором R1 и R2 идентичны и представляют собой метил или этил.4. The use of claim 3, wherein R 1 and R 2 are identical and are methyl or ethyl. 5. Применение по пп. 1-4, в котором из биологически активных веществ готовятся оральные композиции в форме таблеток, микротаблеток, пилюль или гранулятов, в случае необходимости в капсулах или пакетиках. 5. The use of PP. 1-4, in which from the biologically active substances are prepared oral compositions in the form of tablets, microtablets, pills or granules, if necessary, in capsules or sachets. 6. Применение по п. 5, в котором размер или средний диаметр пилюль или микротаблеток находится в области от 300 до 2000 мкм. 6. The use according to claim 5, in which the size or average diameter of the pills or microtablets is in the range from 300 to 2000 microns. 7. Применение по пп. 1-6, в котором композиция находится в виде мягко- или твердожелатиновых капсул. 7. The use of PP. 1-6, in which the composition is in the form of soft or hard gelatin capsules. 8. Применение по одному из пп. 1-7, в котором композиция содержит биологически активное вещество в количестве, соответствующем от 10 до 300 мг фумаровой кислоты. 8. The use according to one of paragraphs. 1-7, in which the composition contains a biologically active substance in an amount corresponding to from 10 to 300 mg of fumaric acid. 9. Применение по пп. 5-8, в котором дозированные единицы лекарственных средств снабжены оболочкой, устойчивой к желудочному соку. 9. The use of PP. 5-8, in which dosage units of drugs are provided with a membrane resistant to gastric juice. 10. Применение по одному из пп. 1-4, в котором лекарственные средства используются форме препаратов для кожного и чрескожного применения, препаратов для парентерального применения и препаратов для ректального применения. 10. The use according to one of paragraphs. 1-4, in which the drugs are used in the form of preparations for skin and percutaneous use, preparations for parenteral administration and preparations for rectal administration. 11. Фармацевтическая композиция в форме микротаблеток или пилюль, содержащая один или более диалкилфумаратов формулы
Figure 00000002

в которой R1 и R2 могут быть одинаковыми или разными, независимо друг от друга линейными, разветвленными или циклическими, насыщенными или ненасыщенными С1-20-алкильными остатками, которые в случае необходимости могут быть замещены галогеном (хлор, фтор, иод, бром), гидроксигруппой, C1-4-алкоксигруппой, нитрогруппой или цианогруппой, и, в случае необходимости, содержащая пригодные носители и вспомогательные вещества, для применения в трансплантационной медицине или для терапии аутоиммунных заболеваний, как полиартрит, рассеянный склероз, юношеский диабет, тиреоидит Хашимото, диффузный токсический зоб (болезнь Грейвса или базедова болезнь), системная красная волчанка (SLE), ксеродерматоз (синдром Шегрена), пернициозная анемия и хронический активный (люпоидный) гепатит, псориаз, псориатический артрит, нейродермит и региональный энтерит Крона.11. A pharmaceutical composition in the form of microtablets or pills containing one or more dialkyl fumarates of the formula
Figure 00000002

in which R 1 and R 2 can be the same or different, independently from each other linear, branched or cyclic, saturated or unsaturated C 1-20 -alkyl residues, which, if necessary, can be replaced by halogen (chlorine, fluorine, iodine, bromine ), hydroxy, C 1-4 alkoxy, nitro or cyano, and, if necessary, contain suitable carriers and adjuvants for use in transplantation medicine or for the therapy of autoimmune diseases such as polyarthritis, multiple sclerosis, w diabetes mellitus, Hashimoto's thyroiditis, diffuse toxic goiter (Graves disease or Bazedova disease), systemic lupus erythematosus (SLE), xerodermatosis (Sjogren's syndrome), pernicious anemia and chronic active (lupoid) hepatitis, psoriasis, psoriatic arthritis and neurodermatitis, neurodermatitis, neurodermatitis . 12. Композиция по п. 11, содержащая диметилфумарат, диэтилфумарат или метилэтилфумарат. 12. The composition according to p. 11, containing dimethyl fumarate, diethyl fumarate or methyl ethyl fumarate. 13. Композиция по п. 11 или 12, содержащая биологически активное вещество в количестве, соответствующем от 10 до 300 мг фумаровой кислоты. 13. The composition according to p. 11 or 12, containing a biologically active substance in an amount corresponding to from 10 to 300 mg of fumaric acid. 14. Применение одного или более диалкилфумаратов для получения фармацевтической композиции в форме микротаблеток или пилюль для терапии аутоиммунных заболеваний выбранных из группы, состоящей из полиартрита, рассеянного склероза, юношеского диабета, тиреодита Хашимото, диффузного токсического зоба (болезни Грейвса или базедовой болезни), системной красной волчанки (SLE), ксеродерматоза (синдрома Шегрена), пернициозной анемии и хронического активного (люпоидного) гепатита. 14. The use of one or more dialkyl fumarates for the preparation of a pharmaceutical composition in the form of microtablets or pills for the treatment of autoimmune diseases selected from the group consisting of polyarthritis, multiple sclerosis, juvenile diabetes, Hashimoto thyroiditis, diffuse toxic goiter (Graves' disease or basic disease), systemic red lupus erythematosus (SLE), xerodermatosis (Sjögren’s syndrome), pernicious anemia, and chronic active (lupoid) hepatitis. 15. Применение по п. 14 одного или более диалкилфумаратов формулы
Figure 00000003

в которой R1 и R2 могут быть одинаковыми или разными, независимо друг от друга линейными, разветвленными или циклическими, насыщенными или ненасыщенными C1-20-алкильными остатками, которые в случае необходимости могут быть замещены галогеном (хлор, фтор, иод, бром), гидроксигруппой, C1-4-алкоксигруппой, нитрогруппой или цианогруппой, для получения фармацевтической композиции для терапии аутоиммунных заболеваний, выбранных из группы, состоящей из полиартрита, рассеянного склероза, юношеского диабета, тиреоидита Хашимото, диффузного токсического зоба (болезни Грейвса или базедовой болезни), системной красной волчанки (SLE), ксеродерматоза (синдрома Шегрена), пернициозной анемии и хронического активного (люпоидного) гепатита.15. The use according to claim 14 of one or more dialkyl fumarates of the formula
Figure 00000003

in which R 1 and R 2 can be the same or different, independently from each other linear, branched or cyclic, saturated or unsaturated C 1-20 -alkyl residues, which, if necessary, can be replaced by halogen (chlorine, fluorine, iodine, bromine ), hydroxy, C 1-4 alkoxy, nitro or cyano for preparing a pharmaceutical composition for the therapy of autoimmune diseases selected from the group consisting of polyarthritis, multiple sclerosis, juvenile diabetes, Hashimoto's thyroiditis, diffuse toxic one goiter (Graves 'disease or Graves' disease), systemic lupus erythematosus (SLE), Sjögren's syndrome (Sjögren's syndrome), pernicious anemia and chronic active (lupoid) hepatitis. 16. Применение по п. 15, в котором остатки R1 и R2 обозначают метил, этил, н-пропил, изопропил, н-бутил, втор. -бутил, трет. -бутил, пентил, циклопентил, 2-этилгексил, гексил, циклогексил, гептил, циклогептил, октил, винил, аллил, 2-гидроксиэтил, 2- и/или 3-гидроксипропил, 2-метоксиэтил, метоксиэтил или 2- или 3-метоксипропил.16. The use of claim 15, wherein R 1 and R 2 are methyl, ethyl, n-propyl, isopropyl, n-butyl, sec. -butyl, tert. -butyl, pentyl, cyclopentyl, 2-ethylhexyl, hexyl, cyclohexyl, heptyl, cycloheptyl, octyl, vinyl, allyl, 2-hydroxyethyl, 2- and / or 3-hydroxypropyl, 2-methoxyethyl, methoxyethyl or 2- or 3-methoxypropyl . 17. Применение по п. 14 или 15, в котором R1 и R2 идентичны и представляют собой метил или этил.17. The use of claim 14 or 15, wherein R 1 and R 2 are identical and are methyl or ethyl. 18. Применение по одному из пп. 14-17, в котором из биологически активного вещества готовятся оральные композиции в форме таблеток, микротаблеток или пилюль в капсулах или пакетиках. 18. The use according to one of paragraphs. 14-17, in which oral compositions in the form of tablets, microtablets or pills in capsules or sachets are prepared from a biologically active substance. 19. Применение по одному из пп. 14-18, отличающееся тем, что размер или средний диаметр пилюль или микротаблеток находится в области от 300 до 2000 мкм. 19. The use according to one of paragraphs. 14-18, characterized in that the size or average diameter of the pills or microtablets is in the range from 300 to 2000 microns. 20. Применение по п. 18, отличающееся тем, что композиция находится в виде мягко- или твердожелатиновых капсул. 20. The use of claim 18, wherein the composition is in the form of soft or hard gelatin capsules. 21. Применение по одному из пп. 14-20, в котором композиция содержит биологически активное вещество в количестве, соответствующем от 10 до 300 мг фумаровой кислоты. 21. The use according to one of paragraphs. 14-20, in which the composition contains a biologically active substance in an amount corresponding to from 10 to 300 mg of fumaric acid. 22. Применение по одному из пп. 18-21, отличающееся тем, что дозированные единицы лекарственных средств снабжены оболочкой, устойчивой к желудочному соку. 22. The use according to one of paragraphs. 18-21, characterized in that the dosage units of drugs are provided with a membrane resistant to gastric juice.
RU2001116566/14A 1998-11-19 1999-10-29 Application of dialkylfumarates for treating "host against transplant" reactions and autoimmune diseases RU2215524C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19853487A DE19853487A1 (en) 1998-11-19 1998-11-19 Use of dialkyl fumarate for treating transplant rejection and autoimmune disease
DE19853487.6 1998-11-19

Publications (2)

Publication Number Publication Date
RU2001116566A true RU2001116566A (en) 2003-04-20
RU2215524C2 RU2215524C2 (en) 2003-11-10

Family

ID=7888396

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2001116566/14A RU2215524C2 (en) 1998-11-19 1999-10-29 Application of dialkylfumarates for treating "host against transplant" reactions and autoimmune diseases

Country Status (34)

Country Link
US (9) US6509376B1 (en)
EP (1) EP1131065B1 (en)
JP (7) JP2002530324A (en)
CN (2) CN1182844C (en)
AT (1) ATE242633T1 (en)
BE (1) BE2014C040I2 (en)
BG (1) BG64837B1 (en)
BR (1) BR9914606A (en)
CA (1) CA2346438C (en)
CY (1) CY2014027I2 (en)
CZ (1) CZ299409B6 (en)
DE (2) DE19853487A1 (en)
DK (1) DK1131065T3 (en)
EE (1) EE04389B1 (en)
ES (1) ES2195664T3 (en)
FR (1) FR14C0051I2 (en)
HK (1) HK1042242B (en)
HU (2) HU226689B1 (en)
IL (2) IL142728A0 (en)
LT (1) LTC1131065I2 (en)
LU (1) LU92488I2 (en)
ME (1) ME00731B (en)
MX (1) MXPA01005007A (en)
NO (3) NO333257B1 (en)
NZ (1) NZ510247A (en)
PL (2) PL205948B1 (en)
PT (1) PT1131065E (en)
RS (1) RS49995B (en)
RU (1) RU2215524C2 (en)
SI (1) SI1131065T1 (en)
SK (1) SK285601B6 (en)
TR (1) TR200101204T2 (en)
WO (1) WO2000030622A2 (en)
ZA (1) ZA200202335B (en)

Families Citing this family (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19853487A1 (en) * 1998-11-19 2000-05-25 Fumapharm Ag Muri Use of dialkyl fumarate for treating transplant rejection and autoimmune disease
DE10000577A1 (en) * 2000-01-10 2001-07-26 Fumapharm Ag Muri Treating mitochondrial diseases, e.g. Parkinson's or Alzheimer's disease or retinitis pigmentosa, using fumaric acid derivative, e.g. mono- or dialkyl fumarate, having succinate dehydrogenase stimulating activity
US6912052B2 (en) * 2000-11-17 2005-06-28 Cymer, Inc. Gas discharge MOPA laser spectral analysis module
DE10101307A1 (en) * 2001-01-12 2002-08-01 Fumapharm Ag Muri Fumaric acid derivatives as NF-kappaB inhibitor
WO2002055063A2 (en) * 2001-01-12 2002-07-18 Fumapharm Ag Fumaric acid amides
US20050259709A1 (en) * 2002-05-07 2005-11-24 Cymer, Inc. Systems and methods for implementing an interaction between a laser shaped as a line beam and a film deposited on a substrate
DE10217314A1 (en) * 2002-04-18 2003-11-13 Fumapharm Ag Muri Carbocyclic and oxacarboncyclic fumaric acid oligomers
AU2003236156A1 (en) * 2003-04-24 2005-01-04 Shin-Jen Shiao Pharmaceutical compositions used for immune disease treatment and improvement
US7277188B2 (en) * 2003-04-29 2007-10-02 Cymer, Inc. Systems and methods for implementing an interaction between a laser shaped as a line beam and a film deposited on a substrate
DE10360869A1 (en) * 2003-09-09 2005-04-07 Fumapharm Ag Use of fumaric acid derivatives for the treatment of heart failure, hyperkeratosis and asthma
AU2004269903B2 (en) * 2003-09-09 2010-09-02 Biogen International Gmbh The use of fumaric acid derivatives for treating cardiac insufficiency, and asthma
DE10342423A1 (en) * 2003-09-13 2005-04-14 Heidland, August, Prof. Dr.med. Dr.h.c. Use of fumaric acid derivatives for the prophylaxis and treatment of genome damage
US6894785B2 (en) * 2003-09-30 2005-05-17 Cymer, Inc. Gas discharge MOPA laser spectral analysis module
US6873418B1 (en) 2003-09-30 2005-03-29 Cymer, Inc. Optical mountings for gas discharge MOPA laser spectral analysis module
CA2478458A1 (en) * 2004-08-20 2006-02-20 Michael Panzara Treatment of pediatric multiple sclerosis
US20140099364A2 (en) 2004-10-08 2014-04-10 Forward Pharma A/S Controlled release pharmaceutical compositions comprising a fumaric acid ester
US20080004344A1 (en) * 2004-11-10 2008-01-03 Aditech Pharma Ab Novel Salts of Fumaric Acid Monoalkylesters and Their Pharmaceutical Use
US7653095B2 (en) * 2005-06-30 2010-01-26 Cymer, Inc. Active bandwidth control for a laser
ATE455783T1 (en) * 2005-07-07 2010-02-15 Aditech Pharma Ag NEW GLUCOPYRANOSE ESTERS AND GLUCOFURANOSE ESTERS OF FUMARIC ACID ALKYL ESTERS AND THEIR PHARMACEUTICAL USE
US20080227847A1 (en) * 2005-07-07 2008-09-18 Aditech Pharma Ab Novel Salts of Fumaric Acid Monoalkylesters and Their Pharmaceutical Use
US20080299196A1 (en) * 2005-10-07 2008-12-04 Aditech Pharma Ab Controlled Release Pharmaceutical Compositions Comprising a Fumaric Acid Ester
WO2007042035A2 (en) * 2005-10-07 2007-04-19 Aditech Pharma Ab Combination therapy with fumaric acid esters for the treatment of autoimmune and/or inflammatory disorders
US7679029B2 (en) * 2005-10-28 2010-03-16 Cymer, Inc. Systems and methods to shape laser light as a line beam for interaction with a substrate having surface variations
US7317179B2 (en) * 2005-10-28 2008-01-08 Cymer, Inc. Systems and methods to shape laser light as a homogeneous line beam for interaction with a film deposited on a substrate
ES2916649T3 (en) 2007-02-08 2022-09-21 Biogen Ma Inc Compositions and uses for the treatment of multiple sclerosis
US20100130607A1 (en) * 2007-02-08 2010-05-27 Ralf Gold Neuroprotection in demyelinating diseases
DE102008030023A1 (en) 2008-06-16 2009-12-17 Eberhard-Karls-Universität Tübingen Universitätsklinikum Medicines for the treatment of parasitic disease
EP2650279A3 (en) 2008-08-19 2014-02-12 XenoPort, Inc. Prodrugs of methyl hydrogen fumarate, pharmaceutical compositions thereof, and methods of use
PT2379063E (en) 2009-01-09 2013-05-03 Forward Pharma As Pharmaceutical formulation comprising one or more fumaric acid esters in an erosion matrix
EP3466420A1 (en) 2009-04-29 2019-04-10 Biogen MA Inc. Dimethyl fumarate for the treatment of friedreich ataxia
EP2533634B1 (en) * 2010-02-12 2015-10-21 Biogen MA Inc. Neuroprotection in demyelinating diseases
US8759535B2 (en) 2010-02-18 2014-06-24 High Point Pharmaceuticals, Llc Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof
WO2011116091A1 (en) 2010-03-17 2011-09-22 Novartis Ag Dispenser
AU2011239512B2 (en) 2010-04-16 2016-01-21 Biogen Ma Inc. Anti-VLA-4 antibodies
US20140163100A1 (en) * 2011-05-26 2014-06-12 Biogen Idec Ma Inc. Methods of Treating Multiple Sclerosis and Preserving and/or Increasing Myelin Content
CN103649041A (en) 2011-06-08 2014-03-19 比奥根艾迪克Ma公司 Process for preparing high purity and crystalline dimethyl fumarate
WO2013076216A1 (en) 2011-11-24 2013-05-30 Synthon Bv Controlled release particles comprising dimethyl fumarate
US20130158077A1 (en) 2011-12-19 2013-06-20 Ares Trading S.A. Pharmaceutical compositions
US9504679B2 (en) 2011-12-19 2016-11-29 Bjoern Colin Kahrs Pharmaceutical compositions comprising glitazones and Nrf2 activators
CN114146080A (en) * 2012-02-07 2022-03-08 比奥根玛公司 Pharmaceutical composition containing dimethyl fumarate
US8952006B2 (en) * 2012-02-07 2015-02-10 Xenoport, Inc. Morpholinoalkyl fumarate compounds, pharmaceutical compositions, and methods of use
JP2015518854A (en) * 2012-05-23 2015-07-06 セリックスビオ プライヴェート リミテッド Compositions and methods for the treatment of multiple sclerosis
WO2014031844A1 (en) 2012-08-22 2014-02-27 Xenoport, Inc. Methods of administering monomethyl fumarate and prodrugs thereof having reduced side effects
AU2013305684B2 (en) 2012-08-22 2016-11-24 Xenoport, Inc. Oral dosage forms of methyl hydrogen fumarate and prodrugs thereof
CN103483194B (en) * 2012-11-30 2016-03-09 杨寅柯 A kind of 2-fluoro fumarate (structural formula I) and preparation method thereof and application
US20140171504A1 (en) 2012-12-14 2014-06-19 Georgia Regents Research Institute, Inc. Methods of Treating Sickle Cell Disease and Related Disorders Using Fumaric Acid Esters
JP6506174B2 (en) 2012-12-21 2019-04-24 バイオジェン エムエー インコーポレイテッド Deuterium-substituted fumaric acid derivatives
KR101379427B1 (en) * 2013-02-13 2014-03-28 경북대학교병원 Composition for preventing or treating renal fibrosis comprising dimethylfumarate
US8669281B1 (en) 2013-03-14 2014-03-11 Alkermes Pharma Ireland Limited Prodrugs of fumarates and their use in treating various diseases
RS57497B1 (en) 2013-03-14 2018-10-31 Alkermes Pharma Ireland Ltd Prodrugs of fumarates and their use in treating various deseases
US10179118B2 (en) 2013-03-24 2019-01-15 Arbor Pharmaceuticals, Llc Pharmaceutical compositions of dimethyl fumarate
WO2014197860A1 (en) 2013-06-07 2014-12-11 Xenoport, Inc. Method of making monomethyl fumarate
US9421182B2 (en) 2013-06-21 2016-08-23 Xenoport, Inc. Cocrystals of dimethyl fumarate
EA201690107A1 (en) 2013-08-26 2016-10-31 Форвард Фарма А/С PHARMACEUTICAL COMPOSITION CONTAINING DIMETHYLFUMATE FOR INTRODUCTION TO LOW DAILY DOSE
CN104415026A (en) * 2013-08-31 2015-03-18 成都渊源生物科技有限公司 Application of deuterated fumaric acid-enriched derivative in treatment of multiple sclerosis
TW201516020A (en) 2013-09-06 2015-05-01 Xenoport Inc Crystalline forms of (N,N-diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate, methods of synthesis and use
US20150079180A1 (en) 2013-09-18 2015-03-19 Xenoport, Inc. Nanoparticle compositions of dimethyl fumarate
CN104434904B (en) * 2013-09-22 2018-09-04 深圳翰宇药业股份有限公司 A kind of preparation method of compound micro pill capsule and its compound micro pill capsule of preparation
CN105848653A (en) * 2013-09-27 2016-08-10 梯瓦制药工业有限公司 Laquinimod combination therapy for treatment of multiple sclerosis
UA120428C2 (en) * 2013-12-12 2019-12-10 Алміралл, С.А. Pharmaceutical compositions comprising dimethyl fumarate
EP3079663A1 (en) 2013-12-13 2016-10-19 Biogen MA Inc. Controlled release dosage form for once daily administration of dimethyl fumarate
EP3110793B1 (en) 2014-02-24 2019-08-21 Alkermes Pharma Ireland Limited Sulfonamide and sulfinamide prodrugs of fumarates and their use in treating various diseases
EP3501510B1 (en) 2014-02-28 2020-07-01 Banner Life Sciences LLC Controlled release enteric soft capsules of fumarate esters
US10098863B2 (en) 2014-02-28 2018-10-16 Banner Life Sciences Llc Fumarate esters
US9326947B1 (en) 2014-02-28 2016-05-03 Banner Life Sciences Llc Controlled release fumarate esters
US9636318B2 (en) 2015-08-31 2017-05-02 Banner Life Sciences Llc Fumarate ester dosage forms
EP3116536A1 (en) 2014-03-14 2017-01-18 Biogen MA Inc. Dimethyl fumarate and vaccination regimens
US9999672B2 (en) 2014-03-24 2018-06-19 Xenoport, Inc. Pharmaceutical compositions of fumaric acid esters
CN104027311A (en) * 2014-05-09 2014-09-10 万特制药(海南)有限公司 Dimethyl fumarate-containing enteric slow-release pellet
WO2016061393A1 (en) 2014-10-15 2016-04-21 Xenoport, Inc. Fumarate compounds, pharmaceutical compositions, and methods of use
DE102014015314A1 (en) * 2014-10-17 2016-04-21 Ppm-Medical Holding Gmbh Means for supporting immune modulation
MA40985A (en) 2014-11-17 2017-09-26 Biogen Ma Inc MULTIPLE SCLEROSIS TREATMENT METHODS
CN104490849A (en) * 2014-11-24 2015-04-08 广东东阳光药业有限公司 High-density dimethyl fumarate enteric-coated granules and preparation method thereof
WO2016089648A1 (en) 2014-12-01 2016-06-09 Vtv Therapeutics Llc Bach 1 inhibitors in combination with nrf2 activators and pharmaceutical compositions thereof
AU2015360502A1 (en) 2014-12-10 2017-06-29 Regents Of The University Of Minnesota Genetically modified cells, tissues, and organs for treating disease
MA41139A (en) 2014-12-11 2017-10-17 Actelion Pharmaceuticals Ltd PHARMACEUTICAL COMBINATION INCLUDING A SIP1 RECEPTOR SELECTIVE AGONIST
KR102283582B1 (en) 2014-12-23 2021-07-30 한미약품 주식회사 A pharmaceutical formulation in the form of mini-tablets containing a fumaric acid ester
CN107847451A (en) * 2015-02-02 2018-03-27 英仕柏集团有限责任公司 Stable dialkyl fumarate composition
EA037666B1 (en) * 2015-02-08 2021-04-28 Алкермес Фарма Айрленд Лимитед Pharmaceutical composition comprising 2-(2,5-dioxopyrrolidin-1-yl)ethyl methyl fumarate and use thereof in medicine
EP3270911A4 (en) * 2015-03-17 2018-08-29 Hetero Labs Limited Pharmaceutical compositions of dimethyl fumarate
US9636321B2 (en) 2015-03-27 2017-05-02 Symbionyx Pharmaceuticals Inc. Compositions and methods for treating psoriasis
WO2016194004A1 (en) 2015-06-01 2016-12-08 Sun Pharmaceutical Industries Ltd. Pharmaceutical compositions of dimethyl fumarate
MA42196A (en) 2015-06-17 2018-04-25 Biogen Ma Inc DIMETHYL FUMARATE PARTICLES AND THEIR PHARMACEUTICAL COMPOSITIONS
US10213411B2 (en) 2015-08-27 2019-02-26 Vijaykumar Rajasekhar Use of prodrugs of fumarates in treating heart failure diseases
WO2017056107A1 (en) 2015-09-28 2017-04-06 Natco Pharma Ltd Pharmaceutical compositions of dimethyl fumarate
WO2017060400A1 (en) 2015-10-07 2017-04-13 Neurovive Pharmaceutical Ab Protected carboxylic acid-based metabolites for the treatment of disesases related to mitochondrial dysfunctions
DE102016103242A1 (en) * 2016-02-24 2017-08-24 Flexopharm Brain Gmbh & Co. Kg Means for supporting immune modulation
CA3003237A1 (en) * 2015-10-28 2017-05-04 Sun Pharmaceutical Industries Limited Pharmaceutical compositions of dimethyl fumarate
US10463642B2 (en) 2016-02-01 2019-11-05 Vijaykumar Rajasekhar Methods of treating heart failure diseases using prodrugs of methyl hydrogen fumarate
WO2017145036A1 (en) * 2016-02-25 2017-08-31 Aurobindo Pharma Ltd Pharmaceutical compositions comprising dimethyl fumarate
CN106265621B (en) * 2016-09-19 2019-05-17 苏州大学 Dimethyl fumarate prevents and treats the application in graft versus host disease(GVH disease) and Graft versus leukemia drug in preparation
GR1009149B (en) 2016-10-25 2017-10-31 Φαρματεν Αβεε Pharmaceutical fomula comprising a fumaric acid ester - production method thereof
TR201616998A1 (en) 2016-11-23 2018-06-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi DELAYED RELEASE DOSING FORMS WITH DIMETHYL FUMARATE
DE102017105036A1 (en) 2017-03-09 2018-09-13 Flexopharm Brain Gmbh & Co. Kg Agent for use in the treatment of dyslipidemia
CN110636838A (en) 2017-06-23 2019-12-31 阿尔米雷尔有限公司 Pharmaceutical composition comprising dimethyl fumarate
KR102197465B1 (en) 2019-05-31 2020-12-31 주식회사 큐라클 Enteric tablet containing dimethyl fumarate as an active ingredient
RU2742745C1 (en) * 2019-09-24 2021-02-10 Акционерное общество "Исследовательский Институт Химического Разнообразия" Dosage form in capsule form containing tablets with dimethyl fumarate
WO2021142062A1 (en) 2020-01-10 2021-07-15 Banner Life Sciences Llc Fumarate ester dosage forms with enhanced gastrointestinal tolerability
EP4114388A1 (en) 2020-03-06 2023-01-11 Actelion Pharmaceuticals Ltd Methods of slowing brain volume loss
CN111418675A (en) * 2020-04-23 2020-07-17 王坤全 Health tea for infants
WO2021144478A2 (en) 2020-05-06 2021-07-22 Imcyse Sa Combination treatment for fumarate-related diseases
WO2022203432A1 (en) 2021-03-25 2022-09-29 주식회사 큐라클 Pharmaceutical composition, containing dimethyl fumarate as active ingredient, showing specific pharmacokinetic parameter
WO2023062511A1 (en) 2021-10-11 2023-04-20 Actelion Pharmaceuticals Ltd Methods of treating multiple sclerosis
CA3220702A1 (en) 2022-02-11 2023-08-17 Actelion Pharmaceuticals Ltd Methods of slowing an increase in brain ventricular volume
CN115590831A (en) * 2022-10-26 2023-01-13 力品药业（厦门）股份有限公司（Cn） Dimethyl fumarate sustained-release micro-tablets and preparation method thereof

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1972109U (en) 1965-10-20 1967-11-09 Qualitrol Corp QUICK VALVE FOR THE PROTECTION OF ELECTRIC EQUIPMENT.
DE1618162B1 (en) 1967-05-20 1971-05-19 Basf Ag Process for the preparation of cyclohexane-1.2.3.4.5.6-hexane-carboxylic acid
US3832287A (en) * 1972-03-02 1974-08-27 Lilly Co Eli Dipeptide antibiotic and method for the production thereof
DE2212369A1 (en) 1972-03-15 1973-09-20 Basf Ag CYCLOHEXANE HEXACARBONIC ACID
DE2530372A1 (en) * 1975-07-08 1977-01-13 Walter Dr Schweckendiek Oral and topical compsns. for psoriasis treatment - contg. fumaric acid (derivs.) and diluent contg. org. acid salts.
DE2621214C3 (en) * 1976-05-13 1981-11-12 Koronis Gmbh Chemisch-Pharmazeutische Praeparate, 5441 Sassen Use of stabilizers in drugs with monoethyl fumarate and its mineral salts
DE2840498C2 (en) * 1978-09-18 1980-04-10 Walter Dr. 6700 Ludwigshafen Schweckendiek Pharmaceutical preparations for the treatment of psoriasis
DE3127432A1 (en) 1981-07-11 1983-02-03 Bayer Ag, 5090 Leverkusen METHOD FOR PRODUCING FUMAR ACID MONOESTER
US4894366A (en) 1984-12-03 1990-01-16 Fujisawa Pharmaceutical Company, Ltd. Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same
US5149695A (en) 1985-01-15 1992-09-22 Speiser Peter P Fumaric acid derivatives, process for the production thereof and pharmaceutical compositions containing same
CH664150A5 (en) * 1985-01-15 1988-02-15 Peter Paul Prof Dr Speiser FUMARIC ACID PRODUCT, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL FORMS CONTAINING THIS.
JPS61194020A (en) 1985-02-22 1986-08-28 Dai Ichi Seiyaku Co Ltd Remedy for retinopathy
GB2176999B (en) 1985-06-22 1989-07-12 Stanley Stewart Davis Sustained release medicament
DE3531597A1 (en) 1985-09-04 1987-03-05 Bioferon Biochem Substanz Use of preparations containing interferon-gamma (IFN-gamma) for the treatment of psoriatic disorders
IL83775A (en) 1987-09-04 1991-12-15 Dexter Chemical Corp Amino acid esters and amides of fumaric acid and pharmaceutical compositions containing them for use in the treatment of psoriasis
US5242905A (en) * 1987-09-04 1993-09-07 Dexter Chemical Corporation Pharmaceutical compositions for the treatment of psoriasis
US5214196A (en) 1987-09-04 1993-05-25 Dexter Chemical Corporation Diethyl ester of di-glycyl fumaramide
US4959389A (en) * 1987-10-19 1990-09-25 Speiser Peter P Pharmaceutical preparation for the treatment of psoriatic arthritis
US5424332A (en) 1987-10-19 1995-06-13 Speiser; Peter P. Pharmaceutical composition and process for the production thereof
DE3834794A1 (en) 1988-10-12 1990-04-19 F Schielein Composition for oral administration to treat psoriasis
AU1271592A (en) 1991-01-18 1992-08-27 Dexter Chemical Corporation Malic acid derivatives and compositions for the treatment of psoriasis
IT1251166B (en) 1991-08-09 1995-05-04 Chiesi Farma Spa GENESERINE DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
DE4494231T1 (en) 1993-06-08 1996-10-17 Raymond K Brown Therapeutic composition and its application
CA2125763C (en) 1993-07-02 2007-08-28 Maurice Kent Gately P40 homodimer of interleukin-12
US5407772A (en) 1993-11-30 1995-04-18 Xerox Corporation Unsaturated polyesters
US7888458B1 (en) 1993-11-30 2011-02-15 John B. Harley Diagnostics and therapy of epstein-barr virus in autoimmune disorders
DK0750616T3 (en) 1994-03-16 2001-07-23 Cenes Ltd Acid addition salts of 2,3,4,5-tetrahydro-1H-3-benzazapine compounds
US6576236B1 (en) 1994-07-01 2003-06-10 Dana Farber Cancer Institute Methods for stimulating T cell responses by manipulating a common cytokine receptor γ chain
GB2291422A (en) 1994-07-18 1996-01-24 Fujisawa Pharmaceutical Co 4-phenyl-pyrido[2,3-b]pyrazin-4-ones
IL110380A0 (en) 1994-07-20 1994-10-21 Agis Ind 1983 Ltd Antiviral topical pharmaceutical compositions
US5589504A (en) * 1994-07-26 1996-12-31 Cornell Research Foundation, Inc. Treatment of newborn jaundice
CN1125141A (en) 1994-12-22 1996-06-26 杭州中美华东制药有限公司 Solid dispersed substance containing cyclosporin A and its applciation of External use dosage form
US6011000A (en) 1995-03-03 2000-01-04 Perrine; Susan P. Compositions for the treatment of blood disorders
JPH1067658A (en) * 1995-09-13 1998-03-10 Takeda Chem Ind Ltd Immunosuppressant
AU6137396A (en) 1995-09-13 1997-04-01 Takeda Chemical Industries Ltd. Immunosuppressant
JP4004567B2 (en) 1996-02-14 2007-11-07 アステラス製薬株式会社 Immunosuppressant containing WB2663B substance
KR970064620A (en) * 1996-03-05 1997-10-13 임성기 Cyclosporin-containing external-use pharmaceutical composition
PT895981E (en) 1996-04-22 2001-05-31 Shionogi & Co COMPOUNDS OF TERFENYL AND MEDICINES CONTAINING THE SAME
IL127166A0 (en) 1996-05-22 1999-09-22 Univ Alberta Type-2 chemokine binding proteins and methods of use therefor
US6046180A (en) 1996-06-17 2000-04-04 Guilford Pharmaceuticals Inc. NAALADase inhibitors
JP2001527517A (en) 1996-07-26 2001-12-25 スーザン・ピー・ペリーネ Therapeutic compositions for blood, viral and cellular diseases
DE19651551C2 (en) * 1996-12-11 2000-02-03 Klinge Co Chem Pharm Fab Opioid antagonist-containing galenic formulation
WO1998027970A2 (en) 1996-12-24 1998-07-02 National Research Council Of Canada Treatment of diseases or prevention of cellular damage caused by oxygen-containing free radicals
US5972363A (en) 1997-04-11 1999-10-26 Rohm And Haas Company Use of an encapsulated bioactive composition
DE19721099C2 (en) * 1997-05-20 1999-12-02 Fumapharm Ag Muri Use of fumaric acid derivatives
JP2001521002A (en) 1997-10-24 2001-11-06 コーネル リサーチ ファンデーション インク． Nutritional supplements for brain metabolic dysfunction
DE19814358C2 (en) * 1998-03-31 2002-01-17 Fumapharm Ag Muri Use of alkyl hydrogen fumarates for the treatment of psoriasis, psoriatic arthritis, neurodermatitis and enteritis regionalis Crohn
DE19839566C2 (en) * 1998-08-31 2002-01-17 Fumapharm Ag Muri Use of fumaric acid derivatives in transplant medicine
DE19848260C2 (en) 1998-10-20 2002-01-17 Fumapharm Ag Muri Fumaric microtablets
DE19853487A1 (en) * 1998-11-19 2000-05-25 Fumapharm Ag Muri Use of dialkyl fumarate for treating transplant rejection and autoimmune disease
DE10000577A1 (en) * 2000-01-10 2001-07-26 Fumapharm Ag Muri Treating mitochondrial diseases, e.g. Parkinson's or Alzheimer's disease or retinitis pigmentosa, using fumaric acid derivative, e.g. mono- or dialkyl fumarate, having succinate dehydrogenase stimulating activity
ES2292564T3 (en) 2000-02-11 2008-03-16 Philadelphia Health And Education Corporation DIFFERENTIATION OF CELLS OF THE OSEA MEDULA IN NEURON CELLS AND ASSOCIATED USES.
WO2002002190A2 (en) 2000-07-05 2002-01-10 Johns Hopkins School Of Medicine Prevention and treatment of neurodegenerative diseases by glutathione and phase ii detoxification enzymes
DE10101307A1 (en) 2001-01-12 2002-08-01 Fumapharm Ag Muri Fumaric acid derivatives as NF-kappaB inhibitor
WO2002055063A2 (en) 2001-01-12 2002-07-18 Fumapharm Ag Fumaric acid amides
CA2463624A1 (en) 2001-10-15 2003-04-24 National Research Council Of Canada Anti-glycation agents for preventing age-, diabetes-, and smoking-related complications
DE10217314A1 (en) 2002-04-18 2003-11-13 Fumapharm Ag Muri Carbocyclic and oxacarboncyclic fumaric acid oligomers
ES2269858T3 (en) 2003-04-28 2007-04-01 Biofrontera Bioscience Gmbh USE OF RILUZOL COMBINED WITH SUITABLE AUXILIARY SUBSTANCES AND ADDITIVES FOR THE TREATMENT OF DISEASES, CHARACTERIZED A HYPERPROLIFERATION OF KERATINOCITS, IN PARTICULAR NEURODERMITIS AND PSORIASIS.
AU2004269903B2 (en) 2003-09-09 2010-09-02 Biogen International Gmbh The use of fumaric acid derivatives for treating cardiac insufficiency, and asthma
DE10342423A1 (en) 2003-09-13 2005-04-14 Heidland, August, Prof. Dr.med. Dr.h.c. Use of fumaric acid derivatives for the prophylaxis and treatment of genome damage
US20050096369A1 (en) 2003-11-04 2005-05-05 Hoang Ba X. Compositions and methods for treating cellular proliferation disorders
RU2007103178A (en) * 2004-06-30 2008-08-10 Комбинаторкс, Инкорпорейтед (Us) WAYS AND REAGENTS FOR TREATMENT OF METABOLIC DISORDERS
US20140099364A2 (en) 2004-10-08 2014-04-10 Forward Pharma A/S Controlled release pharmaceutical compositions comprising a fumaric acid ester
WO2006050730A1 (en) 2004-11-10 2006-05-18 Aditech Pharma Ab Novel salts of fumaric acid monoalkylesters and their pharmaceutical use
CN103169965A (en) 2004-11-19 2013-06-26 比奥根艾迪克Ma公司 Treatment for multiple sclerosis
DE102005022845A1 (en) 2005-05-18 2006-11-23 Fumapharm Ag Thiosuccinic acid derivatives and their use
US20100130607A1 (en) 2007-02-08 2010-05-27 Ralf Gold Neuroprotection in demyelinating diseases
ES2916649T3 (en) 2007-02-08 2022-09-21 Biogen Ma Inc Compositions and uses for the treatment of multiple sclerosis
EP3466420A1 (en) 2009-04-29 2019-04-10 Biogen MA Inc. Dimethyl fumarate for the treatment of friedreich ataxia

Similar Documents

Publication Publication Date Title
RU2001116566A (en) APPLICATION OF DIALKYLFUMARATES FOR THE TREATMENT OF REASONS "OWNERS AGAINST THE TRANSPLANT" AND AUTOIMMUNE DISEASES
RU99127306A (en) APPLICATION OF FUMAR ACID DERIVATIVES
JP2005097323A5 (en)
CN1029770C (en) Controlled release bases for pharmaceuticals
CN1140267C (en) Compositions for a once a day treatment of cyclooxygenase-2 mediated diseases
ES2292643T3 (en) TREATMENT OF THE COLLATERAL EFFECTS OF STATIN.
RU2001108500A (en) APPLICATION OF FUMARIC ACID DERIVATIVES IN TRANSPLANTATION MEDICINE
CA2065285C (en) Antimalarial compositions
ATE67504T1 (en) INSULIN RECEPTOR, ITS PURIFICATION, ITS PRODUCTION IN RECOMBINANT CELLS, DNA THEREOF, ANTIBODIES AGAINST INSULIN RECEPTOR AND THEIR PRODUCTION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE ANTIBODIES.
KR860001591A (en) Pellet Formulations and Methods for Making the Same
US5760261A (en) Higher fatty acid derivatives of salicylic acid and salts thereof
ES2361284T3 (en) THERAPEUTIC COMBINATIONS.
JPS5948415A (en) Long time active matrix tablet
AU2431702A (en) Process for preparing pharmaceutical compositions for use with soft gelatin formulations
ES2864153T3 (en) New crystal form of dapagliflozin and method of preparation and use of the same
DK15388A (en) PROCEDURE FOR THE PREPARATION OF A DELAY PRODUCT CONTAINING DILTIAZEM WITH A SPECIAL DAILY DOSAGE
IL44628A (en) Pharmaceutical compositions containing 4-hydroxy-3-nitrocoumarin derivatives,certain such novel derivatives and their preparation
RU2220727C2 (en) Dehydroepiandrosterone-containing composition and methods for its making and application
JPH04210638A (en) Pharmaceutical preparation for oral administration in fluid form
JP3982889B2 (en) Pharmaceutical preparations containing ibuprofen
KR950013577B1 (en) Carboxamide derivatives
JPH01246218A (en) Immunoregulator
KR20070024521A (en) The combination for treating hyperlipemia
US2910403A (en) Anti hypertensive compositions comprising 2-methyl-5, 8-dimethoxychromone and acetamides
AU733802B2 (en) Sustainedly releasing agents for medicines and sustainedly released medicinal compositions containing the same